Scientists develop an mRNA technology approach to target Alzheimer’s disease

Trending 2 weeks ago

Scientists astatine The Florey person developed an mRNA exertion attack to target nan toxic macromolecule tau, which builds up successful patients pinch Alzheimer's illness and different dementias. 

To date, mRNA has been predominantly utilized for vaccines, including those utilized to conflict COVID-19. 

New investigation published coming successful Brain Communications establishes The Florey arsenic a cardinal subordinate successful nan mRNA field, pinch Dr Rebecca Nisbet taking nan exertion successful a caller direction. 

This is nan first clip mRNA has been explored for usage successful Alzheimer's disease. Our activity successful compartment models demonstrates that this exertion tin service purposes different than vaccine development." 

Dr. Rebecca Nisbet

She likened mRNA to an instruction manual for cells. 

"Once delivered to nan cell, nan compartment sounds nan mRNA and makes an antibody." 

The Florey squad utilized mRNA to instruct cells successful compartment models to create RNJ1, an antibody Dr Nisbet developed to target tau, a macromolecule that clumps successful nan encephalon cells of dementia patients. 

"This is nan first time, to our knowledge, a tau antibody has been capable to straight prosecute tau wrong nan cell." 

First writer connected nan paper, PhD student Patricia Wongsodirdjo said: "Our method tin beryllium applied to immoderate therapeutic antibody, and we envision that this strategy, erstwhile mixed pinch nanoparticle packaging, will heighten targeting of toxic molecules successful nan encephalon and amended diligent outcomes compared to accepted strategies." 

Dr Nisbet said RNJ1 still needed further research. 

She said emerging Alzheimer's treatments, specified arsenic lecanemab, which is approved successful nan USA and nether information successful Australia, are promising but costly to make and are not an businesslike measurement of getting an progressive antibody into encephalon cells. 

"With accepted antibodies, specified arsenic lecanemab, nan mini magnitude of antibody that does participate nan encephalon tin region immoderate harmful plaque that lies extracurricular our encephalon cells but can't entree toxic proteins specified arsenic tau, which is located successful our encephalon cells," Dr Nisbet said. 


Journal reference:

Wongsodirdjo, P., et al. (2024). mRNA encoded antibody attack for targeting extracellular and intracellular tau. Brain Communications.